ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer

FEBS Journal

Volumn 281, Issue 10, 2014, Pages 2431-2442

  Heckler, Mary M ^a   Thakor, Hemang ^a   Schafer, Cara C ^a   Riggins, Rebecca B ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ERK MAPK; estrogen related receptor ; tamoxifen; transcription

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RELATED RECEPTOR GAMMA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REGULATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; THERAPY RESISTANCE; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ER+ BREAST CANCER; ERK/MAPK; ESTROGEN-RELATED RECEPTOR Γ; TAMOXIFEN; TRANSCRIPTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, ESTROGEN; RECOMBINANT PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84901242212     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12797     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, &, Forman D, (2011) Global cancer statistics. CA Cancer J Clin 61, 69-90.
2. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, et al,. (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771-784.
3. Kaufmann M, &, Pusztai L, & Biedenkopf Expert Panel Members (2011) Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an international expert panel. Cancer 117, 1575-1582.
4. Riggins RB, Schrecengost RS, Guerrero MS, &, Bouton AH, (2007) Pathways to tamoxifen resistance. Cancer Lett 256, 1-24.
5. Musgrove E, &, Sutherland R, (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9, 631-643.
6. Giuliano M, Schifp R, Osborne CK, &, Trivedi MV, (2011) Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast 20 (Suppl 3), S42-S49.
7. Benoit G, Cooney A, Giguere V, Ingraham H, Lazar M, Muscat G, Perlmann T, Renaud J, Schwabe J, Sladek F, et al,. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol Rev 58, 798-836.
8. Riggins RB, Mazzotta MM, Maniya OZ, &, Clarke R, (2010) Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. Endocr Relat Cancer 17, R213-R231.
9. Eichner LJ, &, Giguère V, (2011) Estrogen related receptors (ERRs): a new dawn in transcriptional control of mitochondrial gene networks. Mitochondrion 11, 544-552.
10. Giguere V, (2008) Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev 29, 677-696.
11. Deblois G, &, Giguère V, (2013) Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond. Nat Rev Cancer 13, 27-36.
12. Bianco S, Sailland J, &, Vanacker JM, (2011) ERRs and cancers: effects on metabolism and on proliferation and migration capacities. J Steroid Biochem Mol Biol 130, 180-185.
13. Kamarajugadda S, Stemboroski L, Cai Q, Simpson NE, Nayak S, Tan M, &, Lu J, (2012) Glucose oxidation modulates anoikis and tumor metastasis. Mol Cell Biol 32, 1893-1907.
14. Ariazi EA, Clark GM, &, Mertz JE, (2002) Estrogen-related receptor α and estrogen-related receptor γ associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 62, 6510-6518.
15. Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J, et al,. (2008) ERRγ mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res 68, 8908-8917.
16. Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Fujimura T, Tsuda H, Osaki A, Saeki T, &, Inoue S, (2011) Estrogen-related receptor γ modulates cell proliferation and estrogen signaling in breast cancer. J Steroid Biochem Mol Biol 123, 1-7.
17. Desouki MM, Liao S, Conroy J, Nowak NJ, Shepherd L, Gaile DP, &, Geradts J, (2011) The genomic relationship between primary breast carcinomas and their nodal metastases. Cancer Invest 29, 300-307.
18. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, et al,. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616.
19. Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, &, Szallasi Z, (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123, 725-731.
20. Butler WB, &, Fontana JA, (1992) Responses to retinoic acid of tamoxifen-sensitive and -resistant sublines of human breast cancer cell line MCF-7. Cancer Res 52, 6164-6167.
21. Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, &, Clarke R, (2010) BCL2 and CASP8 regulation by NF-κB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J 24, 2040-2055.
22. Cook KL, Shajahan AN, Wärri A, Jin L, Hilakivi-Clarke LA, &, Clarke R, (2012) Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness. Cancer Res 72, 3337-3349.
23. Hong H, Yang L, &, Stallcup MR, (1999) Hormone-independent transcriptional activation and coactivator binding by novel orphan nuclear receptor ERR3. J Biol Chem 274, 22618-22626.
24. Lannigan DA, (2003) Estrogen receptor phosphorylation. Steroids 68, 1-9.
25. Murphy LC, Seekallu SV, &, Watson PH, (2011) Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer 18, R1-R14.
26. Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, &, Mertz JE, (2007) Estrogen-related receptor α1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Mol Cancer Res 5, 71-85.
27. Desclozeaux M, Krylova IN, Horn F, Fletterick RJ, &, Ingraham HA, (2002) Phosphorylation and intramolecular stabilization of the ligand binding domain in the nuclear receptor steroidogenic factor 1. Mol Cell Biol 22, 7193-7203.
28. Hammer GD, Krylova I, Zhang Y, Darimont BD, Simpson K, Weigel NL, &, Ingraham HA, (1999) Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of hormone signaling in reproduction and stress. Mol Cell 3, 521-526.
29. Zhang T, Jia N, Fei E, Wang P, Liao Z, Ding L, Yan M, Nukina N, Zhou J, &, Wang G, (2007) Nurr1 is phosphorylated by ERK2 in vitro and its phosphorylation upregulates tyrosine hydroxylase expression in SH-SY5Y cells. Neurosci Lett 423, 118-122.
30. Lee YK, Choi YH, Chua S, Park YJ, &, Moore DD, (2006) Phosphorylation of the hinge domain of the nuclear hormone receptor LRH-1 stimulates transactivation. J Biol Chem 281, 7850-7855.
31. Kronblad A, Hedenfalk I, Nilsson E, Påhlman S, &, Landberg G, (2005) ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERα: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene 24, 6835-6841.
32. Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, et al,. (2009) Phosphorylated ERα, HIF-1α, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 27, 227-234.
33. Hou JY, Rodriguez-Gabin A, Samaweera L, Hazan R, Goldberg GL, Horwitz SB, &, McDaid HM, (2013) Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma. PLoS One 8, e54103.
34. Bardwell L, (2006) Mechanisms of MAPK signalling specificity. Biochem Soc Trans 34, 837-841.
35. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, &, Ahn NG, (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966-970.
36. Tremblay AM, Wilson BJ, Yang XJ, &, Giguere V, (2008) Phosphorylation-dependent sumoylation regulates estrogen-related receptor-α and -γ transcriptional activity through a synergy control motif. Mol Endocrinol 22, 570-584.
37. Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, et al,. (2008) Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci USA 105, 288-293.
38. Donovan JCH, Milic A, &, Slingerland JM, (2001) Constitutive MEK/MAPK activation leads to p27Kip1 deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 276, 40888-40895.
39. Kiang DT, Kollander RE, Thomas T, &, Kennedy BJ, (1989) Up-regulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer. Cancer Res 49, 5312-5316.
40. Lehn S, Fernö M, Jirström K, Rydén L, &, Landberg G, (2011) A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle 10, 956-962.
41. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, &, Knudsen ES, (2007) The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 117, 218-228.
42. Deblois G, Hall J, Perry M, Laganière J, Ghahremani M, Park M, Hallett M, &, Giguère V, (2009) Genome-wide identification of direct target genes implicates estrogen-related receptor α as a determinant of breast cancer heterogeneity. Cancer Res 69, 6149-6157.
43. Chang CY, Kazmin D, Jasper JS, Kunder R, Zuercher WJ, &, McDonnell DP, (2011) The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. Cancer Cell 20, 500-510.
44. Eichner LJ, Perry MC, Dufour CR, Bertos N, Park M, St-Pierre J, &, Giguère V, (2010) miR-378* mediates metabolic shift in breast cancer cells via the PGC-1β/ERRγ transcriptional pathway. Cell Metab 12, 352-361.
45. Liu Z, Li T, Reinhold MI, &, Naski MC, (2014) MEK1-RSK2 contributes to hedgehog signaling by stabilizing GLI2 transcription factor and inhibiting ubiquitination. Oncogene 33, 65-73.
46. Ren Y, Jiang H, Ma D, Nakaso K, &, Feng J, (2011) Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases. Hum Mol Genet 20, 1074-1083.
47. Ren Y, Jiang H, Yang F, Nakaso K, &, Feng J, (2009) Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation. J Biol Chem 284, 4009-4017.
48. Wang H, Liu B, Zhang C, Peng G, Liu M, Li D, Gu F, Chen Q, Dong JT, Fu L, et al,. (2009) Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism. J Pathol 218, 76-85.
49. Tay SP, Yeo CW, Chai C, Chua PJ, Tan HM, Ang AX, Yip DL, Sung JX, Tan PH, Bay BH, et al,. (2010) Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J Biol Chem 285, 29231-29238.
50. Ethier SP, Mahacek ML, Gullick WJ, Frank TS, &, Weber BL, (1993) Differential isolation of normal liminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res 53, 627-635.
51. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, et al,. (2007) Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129, 1065-1079.
52. Dimitri CA, Dowdle W, MacKeigan JP, Blenis J, &, Murphy LO, (2005) Spatially separate docking sites on ERK2 regulate distinct signaling events in vivo. Curr Biol 15, 1319-1324.
53. Cowley SM, &, Parker MG, (1999) A comparison of transcriptional activation by ER α and ER β. J Steroid Biochem Mol Biol 69, 165-175.
54. Takayanagi S, Tokunaga T, Liu X, Okada H, Matsushima A, &, Shimohigashi Y, (2006) Endocrine disruptor bisphenol A strongly binds to human estrogen-related receptor γ (ERRγ) with high constitutive activity. Toxicol Lett 167, 95-105.
55. Bouker KB, Skaar TC, Fernandez DR, O'Brien KA, &, Clarke R, (2004) Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (Faslodex, Fulvestrant). Cancer Res 64, 4030-4039.